Between 15% and 20% of U.S. adults over the age of 65 have obstructive sleep apnea (OSA), according to research in the ...

VGM Group’s acquisition of mask-fitting platform SleepGlad rounds out the company’s respiratory offering and better aligns it ...

Nicko displays the device, a Philips DreamStation, to the camera, noting that it has “now been recalled.” He claims this is because the sound-abating foam inside breaks down, “and then it travels into ...

Carbon dioxide (CO2) is a major respiratory metabolite, and continuous monitoring of CO2 concentration in exhaled breath is ...

Smart beds with adjustable head positioning, like Tempur-pedic's Tempur-Ergo smart power base and the Eight Sleep Pod 4 Ultra ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

These products include airflow generators, masks and ventilation products ... This division is primarily targeting the sleep apnea market while its secondary target markets are people who suffer ...

Obstructive sleep apnea is caused ... Continuous positive airway pressure (CPAP) therapy is the first line of treatment for OSA. It’s administered through a face mask worn at night.

Sleep optimization, or, in other words, ‘sleepmaxxing,’ is getting trendy on social media among those prioritizing their sleep routine for some time already. From sleep trackers, mouth taping, nostril ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...